The Wegovy Pill: Side Effects, OASIS 4 Results and How It Compares With the Shot

The Wegovy pill (on the label, “Wegovy tablets”) is oral semaglutide, 25 mg once a day, for weight management. It’s the same drug as the weekly Wegovy shot, in a tablet you take on an empty stomach^[1]. The FDA approved it on December 22, 2025^[2]. In OASIS 4, the trial behind it, weight fell 13.6% on average over 64 weeks, vs. 2.4% on placebo^[1]. Its most common side effects are digestive, like the shot’s: nausea hit 46.6% of people on the pill and 18.6% on placebo^[5].

This is general information from the label and the published trial, not treatment advice. Whether the pill fits you, or whether switching from the shot makes sense, is a conversation with your prescriber. For every GLP-1 pill side by side, see GLP-1 pills; this page goes deeper on this one.

What the Wegovy pill is (and how it differs from Rybelsus)

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist that mimics a gut hormone involved in appetite. They come in 1.5, 4, 9 and 25 mg strengths^[1]. Each tablet also contains salcaprozate sodium (SNAC), which helps semaglutide get absorbed, mostly in the stomach^[1]. How the molecule works is in the semaglutide guide.

According to the US label, the tablets are indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight and at least one weight-related condition, and to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight^[1]. Unlike the shot, the tablets’ safety and effectiveness haven’t been established in children, and they aren’t approved for the liver disease MASH^[1].

Rybelsus and Ozempic tablets are oral semaglutide too, but their label covers blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes, not weight management^[3]. They also use different strengths that aren’t substitutable on a mg-to-mg basis, even with each other^[3].

How to take it, according to the label

Because so little semaglutide gets through the stomach, the label is strict^[1]:

• One tablet once daily, on an empty stomach in the morning, with water only (up to 4 ounces).
• Swallowed whole: not split, crushed, chewed or dissolved.
• No more than one tablet a day.
• At least 30 minutes before eating, drinking anything or taking other oral medications.
• If a dose is missed, skip it and take the next one the following day.

On dosing, the label starts at 1.5 mg once daily and steps up every 30 days, through 4 and 9 mg, to a 25 mg maintenance dose from day 91; if a step isn’t tolerated, the prescriber can delay it^[1].

Why the rules matter: in the label’s studies, semaglutide absorption was higher with 50 mL of water than with 240 mL (about 8 ounces), and higher after a longer fast following the dose^[1]. That’s why the label allows only a little plain water at pill time. The pill also slows stomach emptying, which can affect other drugs: levothyroxine exposure rose 33% when taken with oral semaglutide, and the label advises monitoring medications that need close control^[1]. If you take several pills in the morning, ask your doctor or pharmacist how to space them.

One label point is specific to the tablet: breastfeeding isn’t recommended, because SNAC and its metabolites reach breast milk. And, as with the shot, Wegovy should be stopped at least 2 months before a planned pregnancy^[1].

Wegovy pill side effects

The US label doesn’t have a separate side-effect table for the tablets. It says that in the 25 mg tablet trial, the types and frequency of common adverse reactions were similar to those of the shot^[1]. For the pill’s own numbers, the best public source is the OASIS 4 results posted on ClinicalTrials.gov, which list every adverse event that affected at least 5% of a group over 71 weeks, related to the drug or not^[5]. Here they are next to the shot’s label table:

Pill figures: ClinicalTrials.gov counts, as percentages^[5]. Shot figures: label Table 3, pooled from three 68-week trials^[1]. The label warns that adverse reaction rates from one drug’s trials can’t be directly compared with another’s^[1], and the same caution applies across two forms of one drug: different trials, different people, and only 204 on the pill. A few points of difference between columns doesn’t show that one form causes more of a symptom.

What the label does report for the tablet specifically^[1]:

• Stopping treatment. 6.9% on the pill and 5.9% on placebo stopped because of side effects; digestive ones accounted for 3.4% and 2%.
• Severe digestive reactions. 2% on the pill vs. 0% on placebo; for the shot, 4.1% vs. 0.9%.
• Gallstones. 2.5% on the pill vs. 1% on placebo; 1.6% vs. 0.7% for the shot.
• Dysesthesia, an abnormal skin sensation such as tingling, burning or sensitive skin: 5% on the pill and no one on placebo. It increased with dose and blood levels.
• Heart rate. The shot raised resting heart rate by 1 to 4 beats per minute, and findings were similar in a trial with the tablets.

The ClinicalTrials.gov record adds that serious adverse events affected 8 of 204 people on the pill (3.9%) and 9 of 102 on placebo (8.8%), with no deaths^[5]. How these symptoms tend to change over the first months is in GLP-1 side effects week by week, with food tips in nausea on GLP-1 medications, constipation on GLP-1 and hair loss on GLP-1.

Warnings in the label

The tablets carry the same warnings as the shot^[1]:

• A boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it’s unknown whether it does in humans. It’s contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Acute pancreatitis, gallbladder disease, low blood sugar (higher risk with insulin or sulfonylureas), kidney injury from dehydration, severe digestive reactions, serious allergic reactions, diabetic eye complications in type 2 diabetes, increased heart rate, and food staying in the stomach during anesthesia or deep sedation.
• It isn’t recommended with severe gastroparesis, or together with other semaglutide products or other GLP-1 drugs.

Persistent severe belly pain, signs of an allergic reaction or a racing heartbeat at rest are reasons to contact your doctor^[1].

OASIS 4 results: what the trial showed

OASIS 4, funded by Novo Nordisk, enrolled 307 adults without diabetes who had a BMI of 30 or more, or 27 or more with a weight-related condition, at 22 sites in four countries^[4]: Canada, Germany, Poland and the US^[5]. Two in three got the pill and one in three placebo, all with diet and activity counseling, for 64 weeks plus 7 weeks of follow-up^[4]. Participants averaged 106 kg (about 234 lb) and a BMI of 38; 79% were women and 92% were White^[1]. In the trial, the dose rose through 3, 7 and 14 mg tablets to 25 mg by week 13^[5]. A plain-language summary is in OASIS 4.

US label figures (Study 7)^[1]:

95% CI (confidence interval): the range where the true effect probably lies. The paper and the EU label report the same trial with a slightly different analysis: −13.6% vs. −2.2%, a difference of −11.4 points (95% CI: −13.9 to −9.0), or 14.2 kg (about 31 lb) on average^[4,6]. Both count everyone randomized, including the 18% on the pill and 25.5% on placebo who stopped the study drug^[1]. If everyone had stayed on treatment, the EU label estimates −16.6% vs. −2.8%^[6].

Other changes in the US label were small: systolic blood pressure fell 7 mmHg vs. 5.4 on placebo, and HbA1c 0.3 points vs. 0.1, from a normal-range 5.7%^[1]. These weren’t part of the trial’s formal testing.

The limits, plainly:

• It’s small: 205 people on the pill and 102 on placebo^[4].
• No one with diabetes. The tablets haven’t been studied for weight reduction in adults with type 2 diabetes, and in that group average semaglutide levels from the 25 mg tablet were lower than from the 2.4 mg shot (about 44 vs. 68 nmol/L)^[1].
• Not very diverse: over 9 in 10 participants were White^[1].
• Only against placebo. It says nothing direct about the pill vs. the shot.

Wegovy pill vs. the shot: how they compare

No published trial has compared the Wegovy pill with the Wegovy shot head to head. Here’s what the evidence does say:

• Same molecule, very different absorption. The shot is 89% bioavailable; the tablet, about 1% to 2%^[1]. That’s why the oral dose is so much larger: 25 mg a day adds up to 175 mg a week, against 2.4 mg in a weekly shot.
• Similar levels on average, wider spread. Without type 2 diabetes, the label predicts semaglutide levels from the 25 mg tablet comparable to the 2.4 mg shot, but 90% of people fell between 27 and 186 nmol/L on the tablet vs. 51 and 110 nmol/L on the shot^[1]. Some people absorb a lot more than others.
• Results across separate trials. In STEP 1 (Study 2 in the label), the shot produced −14.9% vs. −2.4% on placebo at 68 weeks^[1]. The EU label concludes that efficacy and safety were similar between OASIS 4 and STEP 1, although some patients haven’t achieved the same exposure with the 25 mg tablet as with the 2.4 mg injection^[6]. An indirect comparison funded by Novo Nordisk estimated a 1.01-point difference in weight loss favoring the shot (95% CI: −1.61 to 3.63), which isn’t a clear difference^[7].
• Routine. A daily pill with a fasting window, or a weekly shot at any time^[1]. The pill avoids needles; the shot avoids the morning wait and the extra rules around other pills.
• Switching. The label describes how to move between the two, pairing the 25 mg pill with the 2.4 mg shot, and suggests considering the shot for people with type 2 diabetes who don’t respond well enough to the tablets^[1]. Whether and when to switch is your prescriber’s decision.

Neither form is “better” across the board; it depends on the person and how they tolerate each. To put the numbers in context, see how much weight people lose on GLP-1 medications, and for the other weekly options, Zepbound vs. Wegovy and Ozempic vs. Wegovy.

Who it’s for, according to the label

Beyond the indication above^[1]:

• Adults only; safety and effectiveness haven’t been established in children.
• Not for people with a personal or family history of medullary thyroid carcinoma or MEN 2, or a prior serious allergic reaction to semaglutide or the tablet’s ingredients.
• If pregnancy is recognized, the label says to stop Wegovy used for weight reduction.
• The indication doesn’t exclude type 2 diabetes, but the tablets weren’t studied for weight in that group, as noted above^[1].

Availability and cost

In the US, the FDA approved Wegovy tablets in 1.5, 4, 9 and 25 mg on December 22, 2025, as a prescription drug^[2]. What you pay depends on your insurance and plan, and list prices change, so I don’t repeat them here: the monthly cost calculator has the dated list price with its source.

Outside the US: the European Commission added the tablets to Wegovy’s EU authorization on July 14, 2026^[8]. In Spain they’re listed as authorized since July 22, 2026, but not marketed, as of October 5, 2026^[9]. In Mexico, Novo Nordisk announced on August 18, 2026 that the health regulator, COFEPRIS, had approved the 25 mg tablets, with launch expected in the coming quarters^[10]. I haven’t found a COFEPRIS notice confirming it, so that’s the company’s word.

FAQ

Is the Wegovy pill the same as Rybelsus?

Same active ingredient, oral semaglutide, and the same empty-stomach routine^[1,3]. But Rybelsus and Ozempic tablets are approved for type 2 diabetes, and the Wegovy pill for weight management and cardiovascular risk reduction, with its own trial and doses^[1,3]. They aren’t interchangeable on your own.

Does the Wegovy pill work as well as the shot?

There’s no head-to-head trial. Across separate trials, the pill lost 13.6% in OASIS 4 and the shot 14.9% in STEP 1, and the EU label calls efficacy similar, though some people don’t reach the same drug levels on the pill^[1,6]. A Novo Nordisk-funded indirect comparison found no clear difference^[7].

What are the most common Wegovy pill side effects?

In OASIS 4: nausea (46.6%), vomiting (30.9%), constipation (20.1%), indigestion (18.1%) and diarrhea (17.6%), against 5.9% to 18.6% on placebo^[5]. The label says the types and frequency were similar to the shot’s^[1].

Can I drink coffee with the Wegovy pill?

Not at pill time. The label says to take it with water only, up to 4 ounces, and wait at least 30 minutes before eating or drinking anything else^[1].

Is the Wegovy pill available in Spain or Mexico?

In Spain it’s authorized but not marketed as of October 5, 2026^[9]. In Mexico, Novo Nordisk reported COFEPRIS approval in August 2026, with no launch date yet^[10].

Why have I lost so little in my first months on the Wegovy pill, and is daily nausea normal?

The first three months are mostly the build-up: the pill reaches the 25 mg maintenance dose only from day 91, so a slow start says little yet^[1]. The EU label describes weight loss in OASIS 4 as starting early and continuing throughout the trial, with the main result at week 64; the figures are in OASIS 4 results^[6]. On nausea, the US label says digestive reactions in the Wegovy injection trials were most frequently reported during dosage escalation^[1], and the EU label says that in OASIS 4 most were mild to moderate and short-lived^[6]. Neither says whether nausea happens every day. If it doesn’t settle, tell your prescriber, who can delay the next dose increase^[1]; the rules in how to take it also affect how much you absorb.